Adrien Morel

Adrien Morel

Auto-generated profile, based on publicly available information

Adrien Morel

School of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT) Universidad del Rosario Bogotá Colombia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
EJElise Jacquin
Elise Jacquin
ABAlice Baraquin
Alice Baraquin
RRRajeev Ramanah
Rajeev Ramanah
XCXavier Carcopino
Xavier Carcopino
AMAdrien Morel
Adrien Morel
JPJean-Luc Prétet
Jean-Luc Prétet
High-risk (HR) human papillomavirus (HPV)-associated carcinogenesis is driven mainly by the overexpression of E7 and E6 oncoproteins following viral DNA integration and the concomitant loss of the E2 open reading frame (ORF). However, the integration of HR-HPV DNA is not systematically observed in cervical cancers. The E2 protein acts as a transcription factor that governs viral oncogene expression. The methylation of CpGs in the E2-binding sites (E2BSs) in the viral long control region abrogates E2 binding, thus impairing the E2-mediated regulation of E7/E6 transcription. Here, high-resolution melting (HRM)–PCR was developed to quantitatively analyze the methylation statuses of E2BS1, E2BS2, and the specificity protein 1 (Sp1)-binding site in 119 HPV16-positive cervical smears. This is a rapid assay that is suitable for the analysis of cervical samples. The proportion of cancer samples with methylated E2BS1, E2BS2, and Sp1-binding site CpGs was 47%, whereas the vast majority of samples diagnosed as being within normal limits, low-grade squamous intraepithelial lesions (LSIL), or high-grade squamous intraepithelial lesions (HSIL) harbored unmethylated CpGs. Methylation levels varied widely, since some cancer samples harbored up to 60% of methylated HPV16 genomes. A pyrosequencing approach was used as a confirmation test and highlighted that quantitative measurement of methylation can be achieved by HRM-PCR. Its prognostic value deserves to be investigated alone or in association with other biomarkers. The reliability of this single-tube assay offers great opportunities for the investigation of HPV16 methylation in other HPV-related cancers, such as head and neck cancers, which are a major public health burden.

22 October 2018 in Human Mutation
Verified
Journal Article
Closed access
PDF file
LPLiliana C. Patiño
Liliana C. Patiño
IBIsabelle Beau
Isabelle Beau
AMAdrien Morel
Adrien Morel
BDBrigitte Delemer
Brigitte Delemer
JYJacques Young
Jacques Young
PLPaul Laissue
Paul Laissue

2 May 2017 in Oncotarget
Verified
Journal Article
Open access
AMAdrien Morel
Adrien Morel
ABAurélie Baguet
Aurélie Baguet
JPJérôme Perrard
Jérôme Perrard
CDCaroline Demeret
Caroline Demeret
EJElise Jacquin
Elise Jacquin
JPJean-Luc Prétet
Jean-Luc Prétet
5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression 5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression

14 February 2022 in Journal of Pregnancy
Verified
Journal Article
Open access
PDF file
LPLaura Parada-Niño
Laura Parada-Niño
LLLuisa Fernanda Castillo Leon
Luisa Fernanda Castillo Leon
AMAdrien Morel
Adrien Morel
Preeclampsia (PE) is a hypertensive disease that affects pregnant women after 20 weeks of gestation. This disease is associated with an important risk of maternal and fetal mortality. PE is described as a placental pathology because, after delivery, most women recover normal arterial pressure. Poor invasion of the spiral arteries is a phenomenon well described in PE; this leads to a hypoxic uterine bed and imbalance of antiangiogenic and proangiogenic factors in the uteroplacental region, which in turn triggers the disease phenotype. The causes of the pathology are unclear; nevertheless, numerous approaches, including next-generation sequencing, association, and case control and miRNA studies, have shed light on the genetic/molecular basis of PE. These studies help us better understand the disease to advance new treatment strategies.

1 March 2016 in Journal of Virological Methods
Verified
Journal Article
Closed access
HBHeidi Barth
Heidi Barth
AMAdrien Morel
Adrien Morel
CMChristiane Mougin
Christiane Mougin
GAGerlinde Averous
Gerlinde Averous
MLMichèle Legrain
Michèle Legrain
FSFrançoise Stoll-Keller
Françoise Stoll-Keller

1 December 2020 in The Application of Clinical Genetics
Verified
Journal Article
Open access
PDF file
CVCamilo Andres Velandia-Piedrahita
Camilo Andres Velandia-Piedrahita
AMAdrien Morel
Adrien Morel
DFDora Fonseca
Dora Fonseca
VHVictor Manuel Huertas-Quiñones
Victor Manuel Huertas-Quiñones
DCDavid Castillo
David Castillo
RCRodrigo Cabrera
Rodrigo Cabrera
The ELN gene encodes elastin, a fundamental protein of the extracellular matrix that confers elasticity to different tissues including blood vessels. The formation of elastin fibers is a complex process involving monomer coacervation and subsequent crosslinking. Mutations in exons 1– 29 of the ELN gene have been linked to supravalvular aortic stenosis (SVAS) whereas mutations in exons 30– 33 are associated with autosomal dominant cutis laxa (ADCL). This striking segregation has led to the hypothesis that distinct molecular mechanisms underlie both diseases. SVAS is believed to arise through haploinsufficiency while ADCL is hypothesized to be caused by a dominant negative effect. Here, we describe a patient with SVAS harboring a novel splice-site mutation in the last exon of ELN. The location of this mutation is not consistent with current knowledge of SVAS, since all mutations reported in the C-terminus have been found in ADCL patients, and a thorough evaluation did not reveal significant skin involvement in this case. RT-PCR analysis of skin tissue showed that C-terminal mutations in the region can lead to the production of aberrant transcripts through intron retention and activation of cryptic splice sites and suggest that disruption of the very last exon can lead to functional haploinsufficiency potentially related to SVAS.